Peptides are increasingly entering drug development pathways as potential active pharmaceutical ingredients due to their large chemical space, relative ease of synthesis, ready availability of low cost starting materials and general low toxicity. As a result, approximately 60 peptide-based drugs have been approved by the FDA, 140 peptidic drugs are currently under evaluation in clinical trials and a further 500 peptides are in development. Success stories include the prostate cancer drug Lupron™ from Abbott Laboratories, with global sales of more than US$2.3 billion in 2011. Understandably, research into the area of new peptide drugs is at an all-time high.
With synthesis visualization software, higher loading capacity in purification, and effective evaporation technology, Biotage has developed a suite of technology to support the whole peptide workflow.
Download the white paper below (PPS468)
New Method for Analysis of Environmental Pesticides in Water
"I Was Surprised that Everything Worked So Well". A Researcher on Moving to Automated Sample Prep
Notice of Discontinuation of Biotage® SNAP Flash Columns
New Biotage® VacMaster™ Disk - Vacuum Extraction with Rugged Versatility
Extract THC and its Metabolites from Human Hair - New Application Note